A detailed history of Credit Suisse Ag transactions in Day One Biopharmaceuticals, Inc. stock. As of the latest transaction made, Credit Suisse Ag holds 47,149 shares of DAWN stock, worth $591,248. This represents 0.0% of its overall portfolio holdings.

Number of Shares
47,149
Previous 47,149 -0.0%
Holding current value
$591,248
Previous $688,000 13.08%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 08, 2024

BUY
$9.68 - $15.37 $50,336 - $79,924
5,200 Added 12.4%
47,149 $688,000
Q3 2023

Nov 13, 2023

SELL
$11.22 - $14.86 $173,382 - $229,631
-15,453 Reduced 26.92%
41,949 $514,000
Q2 2023

Aug 11, 2023

BUY
$11.74 - $14.47 $673,899 - $830,606
57,402 New
57,402 $685,000
Q4 2022

Feb 13, 2023

SELL
$18.77 - $22.0 $2,928 - $3,432
-156 Reduced 99.36%
1 $0
Q3 2022

Nov 10, 2022

BUY
$16.44 - $26.57 $2,202 - $3,560
134 Added 582.61%
157 $3,000
Q2 2022

Aug 12, 2022

BUY
$5.72 - $17.9 $131 - $411
23 New
23 $0

Others Institutions Holding DAWN

About Day One Biopharmaceuticals, Inc.


  • Ticker DAWN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 73,461,104
  • Market Cap $921M
  • Description
  • Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric pa...
More about DAWN
Track This Portfolio

Track Credit Suisse Ag Portfolio

Follow Credit Suisse Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.